Abstract In this study, we investigated whether activated T cells (ATC) armed with bispecific antibodies (aATC) can inhibits tumor growth and MDSC development in a Th 1 cytokine-enriched (IL-2 and IFN-c) microenvironment. Cytotoxicity mediated by aATC was significantly higher (P \ 0.001) against breast cancer cell lines in the presence of Th 1 cytokines as compared with control co-cultures. In the presence of aATC, CD33
Introduction
A growing body of evidence suggests that host immune cells with a suppressive phenotype limit the efficacy of immunotherapy regimens and facilitate tumor progression [1] [2] [3] [4] . Among the suppressor cell types, regulatory T cells (T regs ), tumor-associated macrophages, and myeloidderived suppressor cells (MDSC) are key suppressor cell populations that accumulate and mediate immune tolerance in tumors and secondary lymphoid tissues in hosts with advanced malignancies [5] [6] [7] . MDSC are defined as a Lin -HLA-DR -CD33 ? cells that are associated with disease progression and tumor burden and possess potent ability to suppress tumor-specific T-cell responses through the induction of T-cell anergy and the development of T regs [8, 9] . Inhibition of MDSC function has been shown to delay tumor growth, suggesting that MDSC-mediated immune suppression can be reversed [10, 11] .
Many cytokines, including interleukin 6 (IL-6), interleukin 13 (IL-13), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte-stimulating factor (G-CSF) and interferon c (IFN-c), have been implicated in the development and induction of effector functions of MDSC [9, [12] [13] [14] [15] [16] . Tumors themselves can release IL-6, IL-13, GM-CSF and G-CSF that in turn can lead to the recruitment and differentiation of granulocytic and monocytic precursors [17] possibly through the activation of the STAT3 signal transduction pathway [3, 18] . In our phase I clinical trial involving stage IV breast cancer patients who received activated T cells (ATC) armed with anti-CD3 9 anti-Her2/neu bispecific antibody (Her2Bi), high levels of specific cytotoxicity by PBMC and circulating Th 1 cytokines were observed [19, 20] . Since Th 1 cytokine IFN-c has been implicated in the induction and activation of MDSC, we asked whether: (1) 
/CD33
? MDSC populations was reduced with further reduction and attenuation of their suppressive activity in presence of aATC.
Materials and methods

Cell lines
The human breast cancer (BrCa) cell lines (SK-BR-3 and MDA-MB-231) were maintained in RPMI-1640 or DMEM culture media (Lonza Inc., Allendale, NJ) supplemented with 10% FBS (Lonza Inc.), 2 mM L-glutamine (Invitrogen, Carlsbad, CA), 50 units/ml penicillin and 50 lg/ml streptomycin (Invitrogen).
Expansion and generation of ATC CD3
? T cells from PBMC were expanded using 20 ng/ml of OKT3 and 100 IU/ml of IL-2 for 14 days at a concentration of 1-2 9 10 6 PBMC/ml in RPMI-1640 supplemented with 10% FBS [21] .
Production of anti-OKT3 9 anti-Her2 bispecific antibodies BiAb were produced by chemical heteroconjugation of OKT3 (a murine IgG2 a anti-CD3 monoclonal antibody, Ortho Biotech, Horsham, PA) and Herceptin (a humanized anti-Her2 IgG 1 , Genentech Inc., San Francisco, CA) as described [21] . Before use, ATC were armed with anti-CD3 9 anti-Her2 (Her2Bi) bispecific antibodies (aATC) using a previously optimized concentration of BiAb (50 ng/10 6 ATC) for 30 min.
3D culture in matrigel
Cells were prepared at a concentration of 2,500 cells/ml in RPMI-1640 or DMEM culture media. Single cells are overlaid on a solidified layer of matrigel measuring approximately 1 mm in thickness as described [22] . Wells were coated with 100% matrigel in 0.25-ml aliquots in 24-well glass bottom plates and allowed to solidify by incubating at 37°C for 30 min. Breast cancer cells were then seeded onto the matrigel base as a single-cell suspension in the medium containing 2% matrigel, in the presence or absence of Th 1 cytokines (10 ng/ml IFN-c and 100 IU/ml IL-2). After 5-7 days when tumor spheres were formed, PBMC were added at 10:1 ratio (10 PBMC/1 tumor cell). Her2Bi-armed ATC were added after 7 days of tumor cell and PBMC 3D co-culture at 10:1 (10 aATC/1 tumor cell) ratio (Fig. 1) . The medium was replaced every 4 days. Tumor spheres were visualized in 5-7 days in 3D culture. In selected experiments, recombinant human MIG/ CXCL9 (100 ng/ml) and IP-10/CXCL10 (100 ng/ml) were added to control cultures in the presence or absence of aATC.
Live cell imaging by inverted confocal microscopy using DiI and DiO dyes
Images were observed with a spinning disk microscope (Perkin Elmer UltraVIEW). Vybrant Ò DiI or DiO was added directly to normal culture media to uniformly label either cell suspensions (activated T cells) or adherent cells (BrCa) and incubated for 5 and 10 min at 37°C, respectively. Tumor spheres stained on the matrigel were washed thrice, similarly non-adherent ATC after loading were spun down, rinsed (39) and resuspended in fresh medium before adding these cells to DiO-labeled tumor cells. Immunostained co-cultures were photographed using a Perkin Elmer UltraVIEW microscope. These dyes uniformly label cells via lateral diffusion in the plasma membrane and do not transfer from labeled to unlabeled cells. DiI (D3911) and DiO (D275) have fluorescence excitation and emission maxima separated by about 65 nm and thus can facilitate two-color labeling.
Cytotoxicity assay
Tumor cells were seeded in 24-well plate at 100,000 cells/ well in volume of 1 ml. Cells were allowed to adhere followed by incubation with aATC for 3-5 days at 1:1 E/T in the presence or absence of Th 1 cytokines. At the end of incubation, 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) was added (40 ll/well of 5 mg/ml MTT in PBS) to each well and incubated in the dark for 3 h at 37°C. After removal of the medium, the dye crystals formed in viable cells were dissolved in isopropanol and detected by reading the absorption at 595 nm in the Tecan Ultra plate reader. Experiments were repeated three times in quadruplicate wells to ensure the reproducibility of results. Cytokine profiling of co-cultures Cytokines were quantitated in culture supernatants collected from matrigel co-cultures in the presence or absence of Th 1 cytokines and in the presence or absence of armed ATC using a 25-plex human cytokine Luminex Array (Invitrogen, Carlsbad, CA) on a Bio-Plex system (Bio-Rad Lab., Hercules, CA). The limit of detection for these assays is \10 pg/ml based on detectable signal of greater than twofold above background (Bio-Rad). Cytokine concentrations were automatically calculated by the BioPlex Manager Software (Bio-Rad).
MDSC isolation
Cells were collected from the digested matrigel cultures. CD33 ? cells were isolated from each culture using anti-CD33 magnetic microbeads (Miltenyi Biotec,). The purity of isolated cell populations was found to be [90% by flow cytometry.
Inhibition of IFN-c-secretion by MDSC
Effect of MDSC on IFN-c production by tumor cell stimulated aATC were detected by IFN-c-specific EliSpot assay (BD Biosciences, San Jose, CA). Positive control EliSpots were assessed after 18 h exposure to the stimulant cells at 10:1 effector to target ratio (E/T). Effect of MDSC was assessed at 10:2:1 ratio (10 aATC: 2 MDSC: 1 tumor cell) in EliSpot plates [28] . Spots were captured and counted on CTL Immunospot counter using Immunospot software version 4 (Cellular Technology Ltd, Shaker Heights, OH).
Inhibition of T-cell proliferation by MDSC
To measure the inhibitory capacity of the MDSC cells, CD33
? cells isolated from matrigel co-cultures were co-incubated with purified CD3 ? T cells. Briefly, purified CD3 ? T cells plated at 0.5 9 10 4 cells/well in 96-well microtiter plates coated with anti-CD3 antibodies (0.5 lg/ ml in PBS), and irradiated (2,500 rads) CD33
? cells were added at various ratios of MDSC/T cells ranging from 1:5 to 1:20 in a final volume of 200 ll of medium. Control wells did not receive any MDSC. The plates were incubated for 72 h at 37°C in humidified 5% CO 2 atmosphere followed by a proliferation assay determined by titer-Glo (Promega).
Inhibition of cytotoxicity by MDSC MDSC suppression of aATC-mediated cytotoxicity directed at specific targets was measured by chromium ( 51 Cr) release assay in 96-well flat-bottomed microtiter plates as described [25] . Briefly, aATC were added to target cells at 10:1 E/T in the absence or presence of CD33
? cells at 10:2:1 (aATC/MDSC/tumor cell) ratio. 51 Cr release was measured after 18 h, and percent cytotoxicity was calculated using the following formula: (experimental cpmspontaneous cpm)/(maximum cpm -spontaneous cpm) 9100.
Statistical analysis
Quantitative data are presented as the mean of at least three or more independent experiments ± standard deviation. A one-way ANOVA was used to determine whether there were statistically significant differences within each experiment. Differences between groups were tested via an unpaired, two-tailed t test.
Results
Th 1 cytokine-enriched microenvironment inhibits tumor growth
First, we explored whether Th 1 cytokine-enriched microenvironment can suppress tumor growth. To this end, we set up the matrigel (3D) cultures of BrCa (SK-BR-3 and MDA-MB-231) cell lines in the presence or absence of IFN-c (10 ng/ml) and IL-2 (100 IU/ml). SK-BR-3 cells over-expresses Her2/neu with epitheloid morphology, whereas MDA-MB-231 is a triple-negative and highly invasive cell line with mesenchymal morphology. Both BrCa cell lines grown under Th 1 cytokine-enriched conditions exhibited smaller tumor spheres in 3D culture as compared to larger tumor spheres in regular growth medium without Th 1 cytokines (Fig. 2a, top at 209 and bottom panel at 1009 magnification).
Th 1 cytokine-enriched microenvironment enhances aATC-mediated tumor cell killing Next, we tested whether the Th 1 cytokine-enriched microenvironment promoted aATC-mediated killing of tumor spheres. This was tested using visual inspection by confocal imaging in 3D cultures and by the MTT assay in 2D cultures. For confocal imaging, BrCa cells were labeled with DiI (red) at day 7 followed by co-culture with DiO (green)-labeled aATC at a 10:1 E/T for an additional 72 h. Confocal imaging show that aATC completely surrounded the tumor spheres, suggesting highly efficient binding of aATC with tumor cells in the presence or absence of Th 1 cytokines. In the presence of Th 1 cytokines, aATC are able to kill tumor spheres effectively as evidenced by a marked decrease in tumor spheres (Fig. 2b) . Figure 2b shows confocal imaging of SK-BR3 (upper panels) and MDA-MB-231(lower panels). These results show that Th 1 cytokines inhibit tumor growth and prime tumor cells for enhanced killing by aATC. Cytotoxicity quantitated by MTT assay in 2D cultures of tumor cells and aATC for 3-5 days at 1:1 ( Fig. 2c ) E/T in the presence or absence of Th 1 cytokines corroborate the results of confocal imaging that Th 1 cytokines render susceptibility to tumor cells for aATC (n = 3; P \ 0.001)-mediated killing (Fig. 2c) . ? /HLA-DR -population slightly increased in the presence of Th 1 cytokines compared to co-cultures without Th 1 cytokines, but the difference was not significant (n = 3). These data suggest that Th 1 cytokine-enriched microenvironment inhibits the development of MDSC. No difference was observed for the Treg CD4
? /CD25 hi / CD127 lo population in the presence or absence of Th 1 cytokines for both cell lines (Fig. 3a, b , bottom panels). -/HLA-DR -MDSC population was highly significant under both control (SK-BR-3, P \ 0.0001; MB-231, P \ 0.03) and Th1 (SK-BR-3, P \ 0.001; MB-231, P \ 0.036) conditions in the presence of aATC compared to without aATC (Fig. 3d) . These data suggest that aATCgenerated microenvironment leads to MDSC elimination and is not dependent on pre-existing Th 1 -enriched microenvironment (n = 3). Unlike MDSC, a significant suppression of CD4 
cytokines-enriched microenvironment and aATC (Fig. 3c, d Her2Bi-armed activated T cells (aATC) attenuates the immunosuppressive ability of MDSC. Next, we tested whether MDSC can exhibit an inhibitory effect on T-cell functions and whether presence of Th 1 cytokines and aATC can modulate the suppressive activity of MDSC.
Suppression of proliferation
For this, cells were sorted into CD33
? MDSC and co-cultured with aATC at 1:5 ratio. T-cell proliferation was suppressed by 70-90% with the addition of CD33
? MDSC; noteworthy is that cultures containing aATC reversed the suppressive ability of CD33 ? MDSC by [50% in the presence or absence of Th 1 cytokines for both cell lines (n = 3; Fig. 4, top panel) .
Suppression of cytotoxicity
Furthermore, we asked whether the addition of MDSC to aATC would inhibit the ability of Her2Bi-armed ATC to kill SK-BR-3 targets at a 1:10:2 ratio (Tumor cell/aATC/ CD33 ? ). The cytotoxicity mediated by aATC directed at SK-BR-3 targets was inhibited by 75% in the presence of CD33
? cells. Interestingly, CD33 ? cells isolated from aATC-containing co-cultures showed a significant attenuation in suppressive ability of CD33
? MDSC for both BrCa cell lines (n = 3; Fig. 4, middle panel) .
Suppression of IFN-c production by aATC
CD33
? MDSC also suppressed IFN-c production in target stimulated aATC by 70-75%. The addition of aATC to the co-cultures attenuated the suppressive ability of CD33 ? MDSC by * 50-60% for both BrCa cell lines (n = 3; Fig. 4, bottom panel) . 
SK-BR-3+PBMC
CD25 hi /CD127 lo .28%
MB-231+PBMC
CD25 hi /CD127 lo .30%
MB-231+PBMC(Th1)
CD25 hi /CD127 lo
1.6%
1.4%
CD25 CD127
SK-BR-3+PBMC SK-BR-3+PBMC (Th1)
Tregs MDSC A B Increased levels of IFN-c, CXCL9 and CXCL10 corroborate with reduced number of MDSC Next, we addressed whether the presence of aATC can influence the cytokine and chemokine profiles. Proinflammatory cytokines IL-1b and IL-6 levels were not altered in the presence of aATC under control and Th 1 cytokineenriched culture conditions compared to without aATC (Fig. 5a ). However, in the presence of aATC MIG/CXCL9 and IP-10/CXCL10 were highly upregulated under both control and Th 1 culture conditions (Fig. 5b) . These data suggest that high levels of IFN-c-induced CXCL9 and CXCL10 may contribute in the suppression MDSC development. To confirm whether increased levels of MIG/ CXCL9 and IP-10/CXCL10 may suppress MDSC 
/CD33
? MDSC populations compared with control culture conditions. More importantly, co-cultures with aATC showed highly significant reduction in MDSC populations regardless of Th 1 cytokines in culture. Furthermore, CD33
? MDSC isolated from cultures containing aATC exhibited reduced suppressive ability, suggesting that aATC were able to attenuate the suppressive activity of MDSC.
In order to understand how Th 1 cytokines and aATC affect the development of MDSC, we analyzed the cytokine profiles in the culture supernatants produced by cells in co-culture under both Th 1 and control conditions with or without aATC. Our data show distinct patterns of cytokines and chemokines in Th 1 cytokine-enriched versus control culture conditions. There were lower levels of cytokines IL-6 (* threefold lower) and IL-1b under Th 1 cytokinesenriched culture supernatants (contained artificially high IFN-c) compared with control culture supernatants for both cell lines. Cytokines provide key signaling in the generation of MDSC; both IL-6 and IL-1b have been shown to promote in vitro generation and the regulation of MDSC and their suppressive function in vivo [23] [24] [25] . Consistent with these reports, our results show decreased levels of IL-6 and IL-1b associated with decreased numbers of MDSC in Th 1 cytokines-enriched culture supernatants. On the other hand, increased levels of IL-6 and IL-1b in control culture supernatants were associated with increased numbers of MDSC underscoring their roles in generation and/or activation of MDSC.
Similar to cytokines, chemokines exhibited different expression patterns between control and Th 1 cytokineenriched culture conditions. Our data show higher levels of IFN-c-induced CXC chemokines such as MIG/CXCL9 (monokine induced by IFN-c) and IP-10/CXCL10 (interferon-inducible protein-10) under Th 1 condition. The higher levels of IFN-c in both cell lines were associated with decreased numbers of MDSC in co-cultures containing Th 1 cytokines. Both, SK-BR-3 and MB-231, cells showed high levels of MCP-1/CCL2 expression under control condition, but levels were reduced under Th 1 condition for MB-231 cells, while MCP-1/CCL2 protein was not detectable for SK-BR-3 in Th 1 cytokines-enriched culture supernatants. MIG/CXCL9 and IP-10/CXCL10) are chemoattractants for IL-2 inducible CXCR3-expressing activated T cells [26, 27] and inhibit the neovascularization induced by powerful angiogenic factors such as MCP-1/ CCL2 through CXCR3 receptor signaling [28] . These CXC chemokines with their ability to recruit T cells and inhibit angiogenic activity, suggest these chemokines as potential anti-tumor factors. However it is not known how these chemokines affect MDSC differentiation in our in vitro 3D model, we hypothesize that these chemokines may potentiate the anti-tumor activity of T cells directly affecting tumor growth which in turn can affect MDSC development and activation. Since aATC can produce IFN-c upon interaction with tumor targets, we hypothesized that presence of aATC in control cultures (resembling the in vivo aATC immunotherapy situation) will induce high levels of IFN-c, CXCL10 and CXCL9 and decrease in MDSC populations. As predicted, control cultures containing aATC showed the similar pattern of cytokines and chemokines as was in Th 1 cytokine-enriched culture condition without aATC. In addition, aATC in control co-cultures downregulated MCP-1/CCL2. Although the pattern of all the cytokines and chemokines was similar to Th 1 cytokines-enriched culture condition except for MCP-1/CCL2, the levels were strikingly lower in cultures containing aATC under both culture conditions. MCP-1/CCL2 is an angiogenic and immunomodulatory factor that is highly chemotactic for monocytes and regulatory T cells [29, 30] while specifically inhibiting
CD8
? T-cell effector functions [31] . Huang et al. [32] . showed that the recruitment of MDSC into tumors is mediated by the CCL2/CCR2 axis and absence of CCL2/CCR2 signaling hindered both MDSC migration and MDSC-promoted tumor growth. In our in vitro 3D model, lower levels of MCP-1/CCL2 may have added effect in suppressing MDSC development in addition to suppressive affects of increased levels of IFN-c, CXCL10 and CXCL9 on MDSC. The role of CXCL10 and CXCL9 in suppressing MDSC population was further evidenced by adding CXCL10 and CXCL9 in control culture condition that resulted in reduced percentage of MDSC (Fig. 5c) .
Chemokines can play dual role in tumor development [33] . Mullins et al. [34, 35] . reported that recruitment of CD8 ? T lymphocytes expressing CXCR3 by chemokines leads to the improvement of patient survival in melanoma. Lack of critical chemokines (CCL2, CXCL9 and CXCL10) in melanoma metastases aggravated disease due to blockage in activated T-cell migration and anti-tumor immunity [36] . On the other hand, the aberrant expression of chemokines in tumors has been shown to induce immunosuppression that favors tumor growth. In hepatocellular carcinoma, high levels of CXCL9 and CXL10 have been associated with inhibition of CXCR3 expression by CD8 ? T lymphocytes, reduction in T-cell tumor infiltration and cytotoxic functions and tumor growth [37] .
The important finding in this study is that IFN-c was able to suppress both tumor growth and MDSC development and rendering tumor cells susceptible to enhanced aATC-mediated killing. However, the mechanisms of multiple effects of IFN-c in our model are not clear, and thus warrants further investigation. While IFN-c has been shown to sensitize tumor cells for enhanced Fas-mediated killing by CTL [38, 39] , role of IFN-c in the development and activation of MDSC remains controversial. However, a recent study demonstrated that activated T cells can mediate MDSC apoptosis through Fas/FasL pathway [40] . IFN-c produced by tumor-specific T lymphocytes has been [41] . Based on our data, we propose a working hypothesis that context-dependent homeostatic balance of various cytokines and chemokines may determine their pro or anti-MDSC activity (Fig. 6) . In summary, we show that either an artificially generated Th 1 cytokine-enriched microenvironment or Th 1 microenvironment generated during aATC-mediated killing of tumor cells, both conditions resulted in a significant reduction in MDSC development or elimination, respectively. Our study suggests that targeted immunotherapy with aATC directed at tumor targets will not only kill tumor cells but may also reduce MDSC populations as part of the targeting response. Further studies are needed to demonstrate the effect of aATC therapy on MDSC in preand post-aATC-treated breast cancer patients. 
